arrow
P

Peter W. Hunt

university of california
H指数:82
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Associations between substance use by type and HIV viral suppression across multiple cohorts in the US

不同类型物质使用与多队列研究中HIV病毒抑制之间的关系

2026-10-030
OAAI
SARS-CoV-2-specific monoclonal antibody AER002 in Long COVID: an exploratory randomized phase 2a mechanistic trial

长新冠中SARS-CoV-2特异性单克隆抗体AER002:一项探索性随机2a期机制试验

2026-09-300
OAAI
Predictors of Abnormal Diffusing Capacity for Carbon Monoxide in Post-pneumonia Ugandans With and Without HIV

乌干达肺炎后人群(合并与未合并HIV)一氧化碳弥散功能异常的预测因子

2026-05-010
PRE
Age modifies the association between sex and the plasma inflammatory proteome in treated HIV

年龄改变了性別与接受治疗的HIV患者血浆炎症蛋白质组之间的关联

2026-02-020
PRE
Body Talk: Correlates of Gut-Immune Dysregulation Phenotypes in People Living with HIV Who Use Methamphetamine

身体对话:人类免疫缺陷病毒感染者使用甲基苯丙胺者肠道-免疫失调表型的相关因素

2025-12-010
OAAI
Brief Report: Sex and HIV Modify Immune Activation Biomarkers in Ugandans Post-Tuberculosis

简报:性别和HIV改变乌干达人结核病后的免疫激活生物标志物

2025-10-010
PRE
Antiretroviral Therapy Intensification With Dolutegravir and/or Maraviroc Did Not Affect HIV-1 Cell-Associated DNA, RNA, and 2-LTR Circles Over 12 Weeks

使用度鲁特韦和/或马拉维若进行抗逆转录病毒疗法强化,并未影响12周内HIV-1细胞相关DNA、RNA及2-LTR环。

2025-10-010
OAAI
Predicting Risk of Cardiovascular Disease Events (PREVENT) score accuracy among people with HIV in the multicenter CNICS cohort

在多中心CNICS队列中,HIV感染者人群中心血管疾病事件(PREVENT)评分的准确性

AIDS
IF3.1
2025-09-040
PREAI
Mpox in People With Human Immunodeficiency Virus: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort

人类免疫缺陷病毒患者的Mpox: 多站点队列中诊断,结果和疫苗有效性的预测因子

2024-10-085
PRE
High-parameter phenotypic characterization reveals a subset of human Th17 cells that preferentially produce IL-17 against M. tuberculosis antigen

高参数表型表征揭示了人类Th17细胞的一个子集,这些细胞优先产生针对结核分枝杆菌抗原的IL-17

2024-04-182
OAAI